Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.

Abstract

BACKGROUND Several phase-III studies have shown improvements in terms of progression-free survival (PFS) with bevacizumab when added to chemotherapy in advanced breast cancer. However, the extent of improvement varied and none of the trials showed benefit in terms of overall survival (OS). PATIENTS AND METHODS All patients with metastatic breast cancer… (More)

Topics

Cite this paper

@article{Gampenrieder2014HypertensionAA, title={Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.}, author={Simon Peter Gampenrieder and Franz Romeder and Claudia Mu\ss and Magdalena Pircher and Sigrun Ressler and Gabriel Rinnerthaler and Rupert Bartsch and Claudia Sattlberger and Brigitte Mlineritsch and Richard Greil}, journal={Anticancer research}, year={2014}, volume={34 1}, pages={227-33} }